We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Adverum Biotechnologies Inc | NASDAQ:ADVM | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.20 | -2.13% | 9.19 | 9.19 | 9.80 | 10.10 | 9.11 | 9.60 | 798,696 | 21:36:37 |
Oral Presentation Details: | |
Event: | Angiogenesis, Exudation, and Degeneration 2020 Meeting |
Title: | Phase1 Study of Intravitreal Gene Therapy with ADVM-022 for Neovascular AMD (OPTIC Trial) |
Session: | Session VII: Treatments for Neovascularization in AMD and ROP |
Date: | February 8, 2020 |
Time: | 2:28 pm EST |
Location: | Mandarin Oriental Hotel, Miami, FL |
Speaker: | David S. Boyer, M.D., senior partner, Retina-Vitreous Associates Medical Group and adjunct clinical professor of ophthalmology with the University of Southern California/Keck School of Medicine in Los Angeles, California. |
Adverum plans to issue a press release relating to the presentation and post the presentation on Adverum’s website at www.adverum.com in the Investors section under the Events and Presentations page at the beginning of the data presentation at Angiogenesis.
KOL Event Details:In addition, Adverum will host an event with expert retinal specialists to discuss the OPTIC data presented at Angiogenesis and the potential opportunity for ADVM-022. The discussion will be held on Sunday, February 9, 2020 beginning at 10:00 am EST. The event will be webcast live from Adverum’s website at www.adverum.com in the Investors section under the Events and Presentations page. A replay of the webcast will be archived and available for replay following the event.
About Adverum BiotechnologiesAdverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. For more information, please visit www.adverum.com.
Investor and Media Inquiries: Investors: Myesha Lacy Adverum Biotechnologies, Inc. mlacy@adverum.com 1-650-649-1257 Media: Cherilyn Cecchini, M.D. LifeSci Communications ccecchini@lifescicomms.com 1-646-876-5196
1 Year Adverum Biotechnologies Chart |
1 Month Adverum Biotechnologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions